In the News
Oncode researchers are featured regularly in the (national) media. This shows that their hard work goes beyond the interest of the Oncology community. We are proud of how our Oncode researchers explain their science to the general public. On this page we share the highlights of their media appearances.
06 - 04 - 2021
Read this Zorgkrant story on Oncode Investigator Titia Sixma and her colleague Meindert Lamers' work on DNA mismatch repair. With the use of cryo-electron microscopy, they were able to visualize the MutS protein and its ability to coordinate the essential DNA repair process from start to finish.
23 - 04 - 2021
L'Oréal-Unesco ‘For Women in Science’ grant
Anne Rios wins a ‘For Women in Science’ grant, worth €25,000 plus the opportunity to work for several months on her research at the Netherlands Institute for Advanced Study (NIAS) in Amsterdam.
15 - 04 - 2021
A digital goldmine
The Hartwig Medical Foundation has a DNA database collecting all self-generated genetic and clinical data, such as treatment outcomes of patients with metastatic cancer in the Nehterlands. It is the largest database in this field worldwide. Oncode Investigator and scientific director of Foundation Edwin Cuppen is interviewed in this ICT & Health article that explains all about the database, its role and application.
14 - 05 - 2021
20 years of mapping the entire human genome
Oncode Investigators Edwin Cuppen and Hans Clevers are interviewed for an extensive article for De Volkskrant about the possibilities created by mapping the entire human DNA 20 years ago.
07 - 06 - 2021
New possibilities for treatment
The research of Oncode Investigator Louis Vermeulen on stomach cancer is thoroughly discussed in the Trouw newspaper, looking into how the findings of his work create new possibilities for treatment, for example by helping healthy stem cells compete with mutants.
15 - 06 - 2021
Zorgkrant reports on how Oncode Investigator Wouter de Laat – in collaboration with biotech company Cergentis and 5 lymphoma experts – developed a novel technology for improved detection of clinically relevant chromosomal rearrangements in tumors.
9 - 07 - 2021
A New biotech company: Xilis
FD announces that Oncode Investigator Hans Clevers raises almost €60 million in seed capital for a new biotech company (Xilis) that aims to improve tailor cancer treatment methods to individual patients. Clevers founded the biotech company two years ago with two associates, without publicizing it at the time.
01 - 09 - 2021
War in Your Body: Rene Bernards on cancer as a chronic disease
Oncode Investigator Rene Bernards talks about cancer as a chronic disease in the first episode of the new season of WNL podcast War in Your Body.
06 - 09 - 2021
Young people are increasingly sombre
Oncode Investigator Lude Franke is interviewed in NOS about his research into the emotional and physical health of 30,000 Dutch people.
08 - 06 - 2021
Oncode Investigator Lude Franke is featured extensively in an NRC article, about a study on the link between people's behaviors and feelings during the pandemic, and their genetic construction.
24 - 06 - 2021
Designed to block
Oncode Investigator Linde Meyaard collaborated with biotech company NextCure, on the NC410 molecule. The drug candidate is designed to block immune suppression mediated by LAIR-1, an immune-modulating receptor located on certain immune cells.
11 - 08 - 2021
Finding all DNA errors at once
Oncode Investigator Emile Voest showed that a one-time analysis of the entire tumor DNA is almost always sufficient to find all DNA errors that may be relevant for treating metastatic cancer.
02 - 09 - 2021
Oncode Institute co-leads PERSIST-SEQ
This new international consortium of academic and industry experts in cancer research will spend the next 5 years intensively investigating why cancer often returns after treatment.
Trouw and De Telegraaf write about this, interviewing Oncode Investigators Rene Bernards and Alexander van Oudenaarden.
08 - 09 - 2021
Genome instability and success of checkpoint inhibitors: form and levels matter
Annals of Oncology feature Oncode Investigator Sarah Derks in their latest podcast. She discusses her recent editorial on an exploratory analysis of predictive molecular biomarkers from the KEYNOTE-061 trial.